Apnimed
Latest round
- Series C
Last raised
- Dec 2022
Total raised
- $142M
Investors
- 7
About Apnimed
Based in the US, Apnimed Inc.Apnimed Inc. is dedicated to developing therapies for obstructive sleep apnea (OSA) and was founded in 2017 in Cambridge, US. In March 2024, Shionogi Pharmaceutical acquired Apnimed Inc. from Tao Capital Partners, Columbia Seligman Investments, Morningside, Seligman Investments, Sectoral Asset Management, Alpha Wave Global, and NexPoint for USD 100 million.Apnimed specializes in the development of innovative oral therapies for obstructive sleep apnea (OSA) and related sleep disorders. Their core product, AD109, is an investigational oral therapy designed to simplify the treatment process for individuals suffering from OSA, particularly those who are untreated or undertreated. AD109 aims to address the underlying neuromuscular dysfunction associated with sleep-related breathing diseases, enhancing oxygenation and promoting restorative sleep.Apnimed’s revenue model is grounded in the commercialization of its novel therapies, particularly their flagship product, AD109, which is currently undergoing Phase 3 clinical trials. Revenue generation will involve direct-to-consumer transactions as well as partnerships with healthcare providers and organizations specializing in sleep medicine. The company’s business structure may encompass licensing agreements or collaborations with pharmaceutical distributors to ensure broader access to their products. Pricing strategies could include subscription models for ongoing treatment options or one-time payments for initial prescriptions, though specific pricing details for AD109 and other potential products have not been publicly disclosed. The acquisition aims to accelerate progress by taking full control of the sleep disorder joint venture and its pipeline.
Who invested in Apnimed
7 investors across 3 rounds
See all investors in Apnimed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Apnimed
Who invested in Apnimed?
Apnimed has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Apnimed raised?
Apnimed has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Apnimed last raise money?
Apnimed's most recent round on record is a Series C, in Dec 2022.
What does Apnimed do?
Apnimed is a pharmaceuticals company.
Where is Apnimed headquartered?
Apnimed is headquartered in Cambridge, US.
Which VCs invest in companies like Apnimed?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Apnimed's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Apnimed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.